<DOC>
	<DOCNO>NCT01202097</DOCNO>
	<brief_summary>The primary objective compare formulation regard impact pulmonary function persistent asthma patient secondary objective clinical control disease 's symptom .</brief_summary>
	<brief_title>A Non- Inferiority Comparative Study Between Seretide® Salmeterol/Fluticasone Eurofarma Patients With Asthma</brief_title>
	<detailed_description>The primary objective compare formulation regard impact pulmonary function persistent asthma patient secondary objective clinical control disease 's symptom . Primary endpoint : Forced expiratory volume 1 second ( FEV1 ) final visit . Secondary endpoint : Expiratory Flow Peak ( EFP ) , symptom score , FEV1 throughout study , use rescue medication , compliance inhaler use , inhaler acceptance preference , frequency observe adverse event .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Sign ICF ≥ 12 year old Have persistent asthma diagnosis , per GINA classification,18 symptom least 6 month clinically stable least 1 month ACQ7 test ( please see Appendix C ) ≤ 3.0 Current use inhale corticosteroid ( 1000 µg beclomethasone dipropionate ) whether combine longterm β2adrenergics relief medication ( salbutamol equivalent ) Initial FEV1 least 40 % normal value expect Blood cortisol evaluation within normal limit . Use oral parenteral corticosteroid within last 3 previous month study Hospitalization need due asthma within last 3 previous month study Active smoker , define consumption cigarette , pipe , cigar form smoke amount within last 3 month Presence severe comorbidities , cardiovascular , renal , liver , neurological , neoplastic , hematological , infectious , dermatological , neurological psychiatric disease chronic respiratory disease asthma Recent ( &lt; 6 month ) expect participation study clinical trial involve drug nature study consist Intolerance allergy component drug evaluate study Pregnant lactate woman Chronic use routine βblockers , orally intravenously , include ophthalmic solution .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>